Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

A person's "bioenergetic age"—or how youthfully their cells generate energy—might be a key indicator of whether they're at ...

Researchers there were conducting part of a nationwide clinical trial of Leqembi, then known by its generic name, lecanemab.

Spatial transcriptomics on human brains parsed microglial reactions to amyloid immunotherapy. Both a vaccine and a therapeutic antibody summoned these cells to plaques. Responders expressed TREM2, ...

Bioenergetic age, or how efficiently cells produce energy, could predict Alzheimer’s risk, with healthy lifestyle choices ...

While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

Chicago area scientists have identified the genes that drive the process of Alzheimer’s disease and are working to make the drug Lecanemab even better by identifying which genes are active ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...